VRTX · Categories · Downgrades
VRTX - Analyst downgrades
Vertex Pharmaceuticals Incorporated (VRTX) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for VRTX
- Vertex Pharma downgraded by Wolfe ResearchWolfe Research downgraded Vertex Pharma from Outperform to Peer Perform
- Vertex Pharma downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Vertex Pharma from Outperform to Market Perform and set a new price target of $503.00
- Vertex Pharma downgraded by Wells Fargo with a new price targetWells Fargo downgraded Vertex Pharma from Overweight to Equal Weight and set a new price target of $460.00
- Vertex Pharma downgraded by OppenheimerOppenheimer downgraded Vertex Pharma from Outperform to Perform
- Vertex Pharma downgraded by Barclays with a new price targetBarclays downgraded Vertex Pharma from Overweight to Equal Weight and set a new price target of $509.00 from $472.00 previously
- Vertex Pharma downgraded by Evercore ISI with a new price targetEvercore ISI downgraded Vertex Pharma from Outperform to In-line and set a new price target of $438.00 from $436.00 previously
- Vertex Pharma downgraded by BernsteinBernstein downgraded Vertex Pharma from Outperform to Mkt Perform
- Vertex Pharma downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Vertex Pharma from Neutral to Underperform and set a new price target of $325.00
- Vertex Pharma downgraded by Maxim GroupMaxim Group downgraded Vertex Pharma from Buy to Hold
- Vertex Pharma downgraded by Canaccord Genuity with a new price targetCanaccord Genuity downgraded Vertex Pharma from Hold to Sell and set a new price target of $379.00 from $332.00 previously
- Vertex Pharma downgraded by Jefferies with a new price targetJefferies downgraded Vertex Pharma from Buy to Hold and set a new price target of $340.00
- Vertex Pharma downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Vertex Pharma from Outperform to Neutral and set a new price target of $250.00
- Vertex Pharmaceuticals downgraded by RBC Capital with a new price targetRBC Capital downgraded Vertex Pharmaceuticals from Outperform to Sector Perform and set a new price target of $269.00
- Vertex Pharmaceuticals downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Vertex Pharmaceuticals from Overweight to Neutral and set a new price target of $218.00 from $323.00 previously
- Vertex Pharmaceuticals downgraded by Stifel with a new price targetStifel downgraded Vertex Pharmaceuticals from Buy to Hold and set a new price target of $213.00 from $244.00 previously
- Vertex Pharmaceuticals downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Vertex Pharmaceuticals from Equal-Weight to Underweight and set a new price target of $202.00
- Vertex Pharmaceuticals downgraded by SVB Leerink with a new price targetSVB Leerink downgraded Vertex Pharmaceuticals from Market Perform to Underperform and set a new price target of $170.00 from $200.00 previously
- Vertex Pharma downgraded by Daiwa Securities with a new price targetDaiwa Securities downgraded Vertex Pharma from Outperform to Neutral and set a new price target of $210.00